Literature DB >> 22099087

Global distribution and epidemiologic associations of Escherichia coli clonal group A, 1998-2007.

James R Johnson1, Megan E Menard, Tsai-Ling Lauderdale, Chris Kosmidis, David Gordon, Peter Collignon, Joel N Maslow, Arjana Tambić Andrasević, Michael A Kuskowski.   

Abstract

Escherichia coli clonal group A (CGA) was first reported in 2001 as an emerging multidrug-resistant extraintestinal pathogen. Because CGA has considerable implications for public health, we examined the trends of its global distribution, clinical associations, and temporal prevalence for the years 1998-2007. We characterized 2,210 E. coli extraintestinal clinical isolates from 32 centers on 6 continents by CGA status for comparison with trimethoprim/sulfamethoxazole (TMP/SMZ) phenotype, specimen type, inpatient/outpatient source, and adult/child host; we adjusted for clustering by center. CGA prevalence varied greatly by center and continent, was strongly associated with TMP/SMZ resistance but not with other epidemiologic variables, and exhibited no temporal prevalence trend. Our findings indicate that CGA is a prominent, primarily TMP/SMZ-resistant extraintestinal pathogen concentrated within the Western world, with considerable pathogenic versatility. The stable prevalence of CGA over time suggests full emergence by the late 1990s, followed by variable endemicity worldwide as an antimicrobial drug-resistant public health threat.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22099087     DOI: 10.3201/eid1711.110488

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


  13 in total

1.  Virulence of Escherichia coli clinical isolates in a murine sepsis model in relation to sequence type ST131 status, fluoroquinolone resistance, and virulence genotype.

Authors:  James R Johnson; Stephen B Porter; George Zhanel; Michael A Kuskowski; Erick Denamur
Journal:  Infect Immun       Date:  2012-02-06       Impact factor: 3.441

2.  Antimicrobial resistance in community-acquired Escherichia coli isolated from urinary infection: Good news or bad?

Authors:  Lindsay E Nicolle
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

3.  Comparative virulence of urinary and bloodstream isolates of extra-intestinal pathogenic Escherichia coli in a Galleria mellonella model.

Authors:  Holly Ciesielczuk; Jonathon Betts; Lynnette Phee; Michel Doumith; Russell Hope; Neil Woodford; David W Wareham
Journal:  Virulence       Date:  2015       Impact factor: 5.882

Review 4.  A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131.

Authors:  Ritu Banerjee; James R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

Review 5.  The population genetics of pathogenic Escherichia coli.

Authors:  Erick Denamur; Olivier Clermont; Stéphane Bonacorsi; David Gordon
Journal:  Nat Rev Microbiol       Date:  2020-08-21       Impact factor: 60.633

6.  Diversity and biofilm-production ability among isolates of Escherichia coli phylogroup D belonging to ST69, ST393 and ST405 clonal groups.

Authors:  Ângela Novais; Claudia Vuotto; João Pires; Carolina Montenegro; Gianfranco Donelli; Teresa M Coque; Luísa Peixe
Journal:  BMC Microbiol       Date:  2013-06-21       Impact factor: 3.605

7.  Regional dissemination of a trimethoprim-resistance gene cassette via a successful transposable element.

Authors:  Amy S Labar; Jennifer S Millman; Ellen Ruebush; Japheth A Opintan; Rima A Bishar; A Oladipo Aboderin; Mercy J Newman; Adebayo Lamikanra; Iruka N Okeke
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

8.  Escherichia coli Sequence Type 131 H30 Is the Main Driver of Emerging Extended-Spectrum-β-Lactamase-Producing E. coli at a Tertiary Care Center.

Authors:  James R Johnson; Brian Johnston; Paul Thuras; Bryn Launer; Evgeni V Sokurenko; Loren G Miller
Journal:  mSphere       Date:  2016-11-23       Impact factor: 4.389

9.  The epidemic of extended-spectrum-β-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx.

Authors:  Lance B Price; James R Johnson; Maliha Aziz; Connie Clabots; Brian Johnston; Veronika Tchesnokova; Lora Nordstrom; Maria Billig; Sujay Chattopadhyay; Marc Stegger; Paal S Andersen; Talima Pearson; Kim Riddell; Peggy Rogers; Delia Scholes; Barbara Kahl; Paul Keim; Evgeni V Sokurenko
Journal:  mBio       Date:  2013-12-17       Impact factor: 7.867

10.  Small Intestine Early Innate Immunity Response during Intestinal Colonization by Escherichia coli Depends on Its Extra-Intestinal Virulence Status.

Authors:  Jérôme Tourret; Benjamin P Willing; Matthew A Croxen; Nicolas Dufour; Sara Dion; Sarah Wachtel; Erick Denamur; B Brett Finlay
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.